Error loading player: No playable sources found
2395
Human and Experimental Cholestasis
Date
May 18, 2024
This product is not available for individual purchase, but it is available as part of the following products:
Full DDW 2024 On Demand Program available now!
SOCIETY: AASLD
| METABOLIC OUTCOMES AND KEY EFFICACY DATA FROM A PHASE 2 TRIAL EVALUATING COMBINATION OBETICHOLIC ACID AND BEZAFIBRATE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS |
| EFFECT OF OBETICHOLIC ACID ON APRI SCORE IN PATIENTS AT HIGHER RISK FOR FIBROSIS, AS DETERMINED BY HIGHER BASELINE FIBROSIS-4 SCORE AND LIVER STIFFNESS: SUBANALYSIS OF THE PHASE 3 POISE TRIAL IN PRIMARY BILIARY CHOLANGITIS |
| MULTI-OMIC SEQUENCING REVEALS DISTINCTIVE GENE EXPRESSION AND DNA METHYLATION ALTERATIONS AS POTENTIAL PREDICTORS OF PRIMARY SCLEROSING CHOLANGITIS DEVELOPMENT IN TREATMENT-NAÏVE PAEDIATRIC ULCERATIVE COLITIS |
| METABOLIC BIOMARKERS PREDICT THE OUTCOME OF UDCA TREATMENT ON PBC PATIENTS WITH HIGH ACCURACY |
| PATHOLOGICAL CHARACTERISTICS AND ROLE OF PLASMA CELLS IN REFRACTORY PRIMARY BILIARY CHOLANGITIS: IMPLICATIONS FOR TARGETED THERAPY |
| FOLIC ACID DEFICIENCY EXACERBATES BILIARY INFLAMMATION IN PRIMARY BILIARY CHOLANGITIS BY PROMOTING CHOLANGIOCYTE SENESCENCE |
Moderators
Indiana University
University of Southern California
Speakers
University of Nevada Las Vegas School of Medicine
Tracks
Related Products
Career Planning for APPs (Hep Associations Committee)
ADDICTION TREATMENT AND HARM REDUCTION IN VIRAL HEPATITIS
It's Not Over: Viral Hepatitis in the Modern Era
SOCIETY: AASLD
AASLD Presidential Plenary
ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS WITH CIRRHOSIS AND HEPATOCELLULAR CANCER IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
